CFTR and cystic fibrosis: Given the lack of evidence regarding the effects of CFTR modulator therapy on glucose tolerance abnormalities (GTA), Misgault and colleagues followed 40 pwCF with GTA homozygous for the F508del (78% had impaired glucose tolerance and 22% had CF-related diabetes) before and after treatment with LUM/IVA [34].